Drug manufacturer tactics to get a handle on 340B sales growth fall into three buckets: Strategic/legal approaches, claims-scrubbing and other operational capabilities, and “demand-side” ways to reduce exposure to 340B discounts. | Source: IQVIA

Drug Companies Are Looking at Multiple Ways to Reduce their 340B Exposure

Some drug manufacturers have grabbed headlines and precipitated lawsuits for ending 340B pricing on drugs dispensed by contract pharmacies. But behind the scenes, drug companies also are investing in other ways to reduce their exposure to 340B program sales, which a major industry consulting firm says have been growing on average by 25 percent per year since 2014.

IQVIA Senior Principal Shiraz Hasan and General Manager Diane Weisbrod described those methods during a webinar yesterday that also addressed estimates of 340B’s size and growth, 340B covered entity and contract pharmacy growth trends, and drivers of manufacturer exposure to 340B drug discounts.

Some drug manufacturers have grabbed headlines and precipitated lawsuits for ending 340B pricing on drugs dispensed by contract pharmacies. But behind the scenes, the companies also are investing in other ways to reduce their exposure to 340B program sales, which a major industry consulting firm says have been growing on average by 25 percent per year since 2014.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer